Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (Δ2(E)-valproate) in healthy male volunteers
- 1 June 1992
- journal article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 14 (3) , 152-158
- https://doi.org/10.1007/bf01962708
Abstract
2-n-Propyl-2(E)-pentenoic acid (Δ2(E)-valproate) was administered to healthy volunteers in oral doses of 50–800 mg. The drug was tolerated well and no significant adverse effects were observed. Pharmacokinetic parameters were determined. Valproate and 3-keto-valproate were detected as metabolites.Keywords
This publication has 19 references indexed in Scilit:
- Fatal Liver Failure in 16 Children with Valproate TherapyEpilepsia, 1988
- Verification of the fetal valproate syndrome phenotypeAmerican Journal of Medical Genetics, 1988
- Valproic acidTeratology, 1987
- Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acidThe Journal of Pediatrics, 1986
- The fetal valproate syndromeAmerican Journal of Medical Genetics, 1984
- Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsyEuropean Journal of Pharmacology, 1984
- Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constant-rate application of the drug and its unsaturated metabolite with an osmotic delivery systemBiopharmaceutics & Drug Disposition, 1982
- A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrationsLife Sciences, 1981
- Effect of metabolites of valproic acid on the metabolism of GABA in brain and brain nerve endingsNeuropharmacology, 1981
- Possible teratogenicity of valproic acidThe Journal of Pediatrics, 1981